Boyce Sarah 4

What Happened
Sarah Boyce, President and CEO and a director of Avidity Biosciences (RNA), sold a total of 14,387 shares of company stock on January 21, 2026. The sales consisted of 6,394 shares at $72.45 each ($463,245) and 7,993 shares at $72.45 each ($579,093), for total proceeds of $1,042,338. These were sales (not purchases) and reflect a routine disposition rather than a buy signal.

Key Details

• Transaction date: January 21, 2026; Price per share: $72.45.
• Shares sold: 6,394 and 7,993 (total 14,387); Total value: $1,042,338.
• Transaction type: Open market sale (reported as "S"); described as a "sell-to-cover" to satisfy tax withholding.
• Footnote: Sales were executed to cover tax withholding on RSUs that vested January 20, 2026. The issuer requires sell-to-cover under its equity plans; the reporting person used an instruction for automatic sale intended to satisfy Rule 10b5-1 affirmative-defense conditions.
• Shares owned after the transaction: not specified in the information provided.
• Filing: Reported on January 23, 2026 (two days after the transactions).

Context
Sell-to-cover transactions are common when restricted stock units vest: the company or executive sells just enough shares to cover taxes rather than paying cash. Such sales are typically routine and do not, by themselves, indicate a change in the insider’s view of the company. The mention of an instruction letter and Rule 10b5-1 relates to prearranged procedures intended to avoid claims of opportunistic trading.